U.S. — Americans' use of GLP-1 injectables for weight loss has reached a record high, according to a recent Gallup poll. The use of these medications has nearly quadrupled since 2024. A retrospective study published in the Journal of the American Heart Association indicated that GLP-1 receptor agonists were associated with lower rates of mortality, major amputations, revascularization, and hospitalization for patients with type 2 diabetes and peripheral artery disease. According to retrospective data published in JAMA Network Open, long-term healthcare costs were higher for patients with obesity and diabetes when treated with GLP-1 drugs compared to those who underwent bariatric surgery. Real-world data from Truveta suggested that individuals using oral semaglutide generally followed the manufacturer's recommended starting dose and titration schedule. Another study in JAMA Network Open, a cohort study, found that initiating continuous glucose monitoring in primary care settings was linked to improved glucose control and fewer hospital visits for insulin-dependent diabetes patients. Research published in eBioMedicine, a crossover trial, observed that acute high-intensity interval exercise suppressed energy intake and elevated metabolic markers in individuals classified as overweight or obese. Meanwhile, a randomized trial detailed in Lancet Diabetes & Endocrinology indicated that long-acting insulin glargine did not outperform intermediate-acting human insulin in treating children and young people with type 1 diabetes in low-resource environments.

Why It Matters

The increase in GLP-1 injectable usage for weight loss marks a shift in how Americans are addressing weight management. This trend occurs alongside ongoing research into various approaches for managing obesity and diabetes, including different medications, lifestyle interventions, and surgical options. These studies provide data on outcomes such as mortality rates, glucose control, exercise effects, and comparative healthcare costs, contributing to the broader understanding of metabolic health interventions.